Search

Displaying results 1221 - 1230 of 10000 in total
  1. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity

  2. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. … Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond.

    Mixtures: FIBRASE SA
  3. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.

  4. Drug

    Technetium Tc-99m pyrophosphate

    go.drugbank.com/drugs/DB09165
    Approved

    A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer.

  6. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the … Moreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well [F3].

  7. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    Viloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A Inhibitors
  8. Drug

    Prothrombin

    go.drugbank.com/drugs/DB11311
    ApprovedInvestigational

    Prothrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  9. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades … [A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.

  10. Drug

    Sulfapyridine

    go.drugbank.com/drugs/DB00891
    ApprovedWithdrawn

    No longer prescribed.

    Synonyms: N-2-Pyridylsulfanilamide, N(1)-Pyridylsulfanilamide